Foghorn Therapeutics Stock Forecast, Price & News

+0.16 (+1.22 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume374,630 shs
Average Volume81,582 shs
Market Capitalization$488.72 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FHTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Foghorn Therapeutics logo

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.23 out of 5 stars

Medical Sector

322nd out of 1,350 stocks

Pharmaceutical Preparations Industry

152nd out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Foghorn Therapeutics (NASDAQ:FHTX) Frequently Asked Questions

Is Foghorn Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Foghorn Therapeutics stock.
View analyst ratings for Foghorn Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Foghorn Therapeutics?

Wall Street analysts have given Foghorn Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Foghorn Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Foghorn Therapeutics' next earnings date?

Foghorn Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, December 3rd 2021.
View our earnings forecast for Foghorn Therapeutics

What price target have analysts set for FHTX?

4 equities research analysts have issued 12-month price targets for Foghorn Therapeutics' shares. Their forecasts range from $23.00 to $27.00. On average, they expect Foghorn Therapeutics' stock price to reach $24.67 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price.
View analysts' price targets for Foghorn Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Foghorn Therapeutics' key executives?

Foghorn Therapeutics' management team includes the following people:
  • Dr. Douglas G. Cole M.D., Founder & Chairman (Age 61, Pay $16.03k)
  • Mr. Adrian H. B. Gottschalk, Pres, CEO & Director (Age 45, Pay $790.27k)
  • Dr. Cigall Kadoch Ph.D., Founder & Director (Age 35, Pay $226.81k)
  • Dr. Carl Peter Decicco Ph.D., Chief Scientific Officer (Age 61, Pay $676.24k)
  • Mr. Michael J. LaCascia, Chief Legal Officer (Age 56, Pay $119.42k)
  • Dr. Samuel Agresta M.D., M.P.H., Chief Medical Officer (Age 49, Pay $511.57k)
  • Dr. Gerald R. Crabtree, Founder & Member of Scientific Advisory Board
  • Dr. Allan Reine, Chief Financial Officer (Age 46)
  • Mr. Carlos Costa, Sr. VP, People & Organization
  • Dr. Steven F. Bellon Ph.D., Sr. VP of Drug Discovery (Age 56)

Who are some of Foghorn Therapeutics' key competitors?

When did Foghorn Therapeutics IPO?

(FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Foghorn Therapeutics' stock symbol?

Foghorn Therapeutics trades on the NASDAQ under the ticker symbol "FHTX."

Who are Foghorn Therapeutics' major shareholders?

Foghorn Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (6.89%), BlackRock Inc. (2.97%), Morgan Stanley (2.65%), Morgan Stanley (2.65%), Vanguard Group Inc. (1.86%) and Geode Capital Management LLC (0.65%). Company insiders that own Foghorn Therapeutics stock include Abu Dhabi Investment Authority and Carl Decicco.
View institutional ownership trends for Foghorn Therapeutics

Which major investors are selling Foghorn Therapeutics stock?

FHTX stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, and FMR LLC.
View insider buying and selling activity for Foghorn Therapeutics
or view top insider-selling stocks.

Which major investors are buying Foghorn Therapeutics stock?

FHTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Morgan Stanley, Vanguard Group Inc., Geode Capital Management LLC, State Street Corp, Northern Trust Corp, and Nuveen Asset Management LLC. Company insiders that have bought Foghorn Therapeutics stock in the last two years include Abu Dhabi Investment Authority, and Carl Decicco.
View insider buying and selling activity for Foghorn Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Foghorn Therapeutics' stock price today?

One share of FHTX stock can currently be purchased for approximately $13.23.

How much money does Foghorn Therapeutics make?

Foghorn Therapeutics has a market capitalization of $488.72 million and generates $430,000.00 in revenue each year. The company earns $-68,800,000.00 in net income (profit) each year or ($6.23) on an earnings per share basis.

How many employees does Foghorn Therapeutics have?

Foghorn Therapeutics employs 95 workers across the globe.

What is Foghorn Therapeutics' official website?

The official website for Foghorn Therapeutics is

How can I contact Foghorn Therapeutics?

The company can be reached via phone at 617-586-3100 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.